Cannabidivarin (CBDV)

Cannabidivarin (CBDV), the propyl-chain homolog of cannabidiol (CBD) first identified by Vollner et al. in 1969 from hashish, is a non-psychoactive phytocannabinoid of escalating research interest in epilepsy, neurodevelopmental disorders, neuroinflammation, and inflammatory bowel disease. Structurally, CBDV differs from CBD solely by the substitution of a three-carbon (propyl) side chain for the five-carbon (pentyl) chain on the resorcinol ring, a modification that preserves the core cyclohexenyl-resorcinol pharmacophore while altering lipophilicity, metabolic handling, and relative target potency. Unlike delta-9-tetrahydrocannabinol and other psychoactive cannabinoids, CBDV exhibits negligible affinity for CB1 and CB2 cannabinoid receptors and produces no intoxicating effects at any dose studied.

The molecular pharmacology of CBDV is characterized by multimodal ion channel and receptor activity. The compound activates and subsequently desensitizes transient receptor potential (TRP) channels of the vanilloid type 1 (TRPV1), vanilloid type 2 (TRPV2), and ankyrin type 1 (TRPA1) subfamilies, while antagonizing TRP channels of the melastatin type 8 (TRPM8) subfamily. This activation-then-desensitization pattern at excitatory TRP channels expressed on hippocampal and cortical neurons constitutes a principal mechanism for the anticonvulsant activity demonstrated across four rodent seizure models (maximal electroshock, audiogenic, pentylenetetrazole, and pilocarpine). CBDV also functions as an antagonist of GPR55, the putative cannabinoid receptor implicated in excitatory neurotransmission and neuronal hyperexcitability, and directly binds the TLR4 co-receptor MD2 with a dissociation constant of approximately 3.9 micromolar, restraining lipopolysaccharide-induced NF-kappaB and MAPK pro-inflammatory signaling cascades. Additional targets include inhibition of diacylglycerol lipase-alpha, the principal biosynthetic enzyme for the endocannabinoid 2-arachidonoylglycerol.

Preclinical pharmacology spans four principal domains. In epilepsy, Hill et al. (2012, 2013) demonstrated dose-dependent anticonvulsant activity of purified CBDV and CBDV-rich botanical extracts across multiple seizure models via a CB1 receptor-independent mechanism, with additive effects when co-administered with cannabidiol or conventional antiepileptic drugs and no significant motor impairment. In Rett syndrome, Vigli et al. (2018) reported that chronic CBDV treatment rescued behavioral alterations, sociability deficits, and brain atrophy in female Mecp2 mutant mice, and Zamberletti et al. (2019) demonstrated complete rescue of cognitive deficits with delayed neurological and motor deterioration in male Mecp2 mutants through normalization of BDNF, IGF-1, and the PI3K/AKT/mTOR signaling axis. In neuroinflammation, CBDV directly bound MD2, suppressed microglial NF-kappaB activation with an IC50 of approximately 1.4 to 1.7 micromolar, and potentiated morphine-mediated analgesia while attenuating opioid tolerance in mouse models. In intestinal inflammation, CBDV attenuated colitis-associated neutrophil infiltration, intestinal permeability, and cytokine production in mice and reduced pro-inflammatory cytokine expression in colonic biopsies from pediatric patients with ulcerative colitis.

Clinical development has been led by GW Pharmaceuticals (now Jazz Pharmaceuticals) under the development code GWP42006. A Phase 2a proof-of-concept trial in 162 adults with inadequately controlled focal seizures (2018) did not meet its primary endpoint, with both active and placebo arms demonstrating approximately 40 percent seizure reduction. A Phase 1 open-label trial in five girls with MECP2-associated Rett syndrome and drug-resistant epilepsy (Hurley et al. 2022) reported a median 82 percent reduction in mean monthly seizure frequency at 10 mg/kg, with four of five patients achieving greater than 50 percent reduction, and the compound was generally well tolerated through 14 to 15 months of treatment. CBDV has received FDA Orphan Drug Designation for Rett syndrome. A single-dose magnetic resonance spectroscopy study in adults with and without autism spectrum disorder (Pretzsch et al. 2019) demonstrated that 600 mg CBDV significantly modulated glutamate concentrations in the basal ganglia, and Phase 2 trials in pediatric autism spectrum disorder are ongoing. Pharmacokinetics are characterized by low oral bioavailability (approximately 6 percent in humans), significant hepatic first-pass metabolism, rapid absorption (Tmax approximately 1 to 2 hours), blood-brain barrier penetration, and a plasma elimination half-life of approximately 3.7 hours in mice. The compound is well tolerated at doses up to 10 mg/kg for extended periods; the principal adverse events are somnolence, diarrhea, and mild appetite changes. This monograph reviews the chemistry, synthesis, multimodal receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a comparative assessment of five phytocannabinoid and non-cannabinoid anticonvulsant candidates against CBDV on five competency standards.